Drug effects on REM sleep and on endogenous depression.
Level 5 - mechanism / opinion, no new human data
Narrative literature review synthesizing pharmacological studies across multiple drug classes without formal systematic review methodology.
PubMed 1970148 · doi:10.1016/s0149-7634(05)80159-9
What was done
A literature review covering the period from 1962 to 1989 examined the REM sleep effects of multiple drug classes, including amine precursors, antidepressants, antihistamines, antipsychotics, barbiturates, benzodiazepines, other hypnotics, cholinergic and noradrenergic agents, ethanol, lithium, and narcotics. The review tested the hypothesis that drugs producing "arousal-type" REM sleep deprivation (RSD)—defined as large, persisting for weeks, and followed by REM rebound—improve endogenous depression. Of 468 relevant papers screened, 215 contributed usable data.
What was found
All drugs that produced arousal-type RSD improved endogenous depression. In addition, four drugs that successfully improved endogenous depression did not produce arousal-type RSD. Quantitative effect sizes, confidence intervals, and individual drug names were not reported in the abstract.
Why it matters
The review provides evidence for a shared pharmacological mechanism between sustained REM sleep suppression and antidepressant action, while showing that REM suppression is not universally required for clinical efficacy.
Limits
The review relies on narrative synthesis across heterogeneous studies spanning nearly three decades rather than a formal systematic review or meta-analysis. The abstract does not specify the four outlier drugs, dosage requirements, patient populations, or quantitative effect sizes.
Cited by
- contradicts Rapid eye movement (REM) sleep has been used as a clinical treatment for depression.